Summary
Angiotensin converting enzyme inhibitors have greatly improved the treatment of patients with chronic heart failure but they are not effective in all patients, and their use may be limited by side effects. There is, therefore, a need to investigate new drugs and to compare their efficacy with angiotensin converting enzyme inhibitors. Flosequinan is a new direct-acting vasodilator that has been shown to be effective in placebo-controlled studies. Patients with chronic heart failure in NYHA classes II or III who remained symptomatic despite at least 80 mg of frusemide daily were recruited from two centers. Following a single-blind placebo run-in period, the patients were randomized double blind to either the addition of captopril or flosequinan for 6 weeks. Following a further 2-week placebo washout period, they were then given the alternative treatment. Symptom-limited treadmill exercise times, scores of perceived exertion, and corridor walk tests were measured at two weekly intervals during the study. Twenty-five patients entered the study, 16 of whom completed without a change in diuretic dose. Five patients were withdrawn while taking captopril and two while taking flosequinan; two were withdrawn during the placebo washout period. For those patients who completed the study, flosequinan increased treadmill exercise tolerance from a mean (SEM) placebo time of 11.5 (1.0) minutes by 2.4 (0.6) (p=0.0002) and captopril from 12.0 (0.8) minutes by 1.2 (0.6) minutes (p=0.08). Comparison of the other measures of efficacy revealed no difference between the groups. In this short-term study flosequinan appeared to be equal in efficacy to captopril.
Similar content being viewed by others
References
Cowley AJ, Rowley JM, Stainer K, Hampton JR. Captopril for heart failure: A placebo controlled trial. Lancet 1982;2:730–732.
Captopril Multicenter Research Group. A placebo controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;4:755–763.
Cowley AJ, Wynne RD, Stainer K, et al. Flosequinan in heart failure: Acute haemodynamic and longer term symptomatic effects. Br Med J 1988;297:169–173.
Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J 1989;61:331–335.
Franciosa JA, Park M, Levin TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981;47: 33–39.
Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med 1970;2:92–98.
Cowley AJ, Stainer K, Wynne RD, et al. Symptomatic assessment of patients with heart failure: Double blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986;2:770–772.
Winer BJ. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill, 1971:796–809.
Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific, 1987.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429–1435.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cowley, A.J., Wynne, R.D., Swami, A. et al. A comparison of the effects of captopril and flosequinan in patients with severe heart failure. Cardiovasc Drug Ther 6, 465–470 (1992). https://doi.org/10.1007/BF00055602
Issue Date:
DOI: https://doi.org/10.1007/BF00055602